Literature DB >> 18478460

[Clinicopathological analysis of synchronous hepatic metastases from colorectal cancer].

Ying-Jiang Ye1, Shan Wang, Jiang Wu, Zhan-Long Shen, Mu-Jun Yin, Xiao-Dong Yang, Ke-Wei Jiang, Jing Zhou.   

Abstract

OBJECTIVE: To screen the clinicopathological factors of synchronous hepatic metastases from colorectal cancer for early diagnosis and therapy.
METHODS: Clinicopathological data of 367 cases with colorectal cancer from Jan. 2003 to Dec. 2006 in our department were collected to set up the database. All the patients were divided into two groups according to hepatic metastases or not. Clinicopathological factors were analyzed, such as age, sex, blood type, tumor family history, hepatitis and cirrhosis history, peritoneal or pelvic metastases, bowel obstruction, CEA, CA19-9, tumor localization and size, histological type, infiltration depth, lymph node metastases etc.
RESULTS: Out of 367 colorectal cancer cases, there were 56 cases with synchronous hepatic metastases from colorectal cancer, accounting for 15.3%. The age, bowel obstruction, peritoneal or pelvic metastases, and tumor invasion depth were associated with the hepatic metastases. The primary tumor located in the right colon resulted in more right lobe hepatic metastases than those in the left lobe. The serum CEA level was associated with hepatic metastases. When serum CEA was more than 22.1 microg/L, the occurrence rate of hepatic metastases increased.
CONCLUSION: Peritoneal or pelvic metastases, bowel obstruction, age and serum CEA level are associated with synchronous hepatic metastases from colorectal cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18478460

Source DB:  PubMed          Journal:  Zhonghua Wei Chang Wai Ke Za Zhi        ISSN: 1671-0274


  1 in total

1.  Association between age and synchronous liver metastasis in female colorectal cancer patients.

Authors:  Lin Wang; Lei Wang; Wenbin Yu; Guangyong Zhang; Lifeng Zhang; Guihong Tian; Sanyuan Hu
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-01       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.